Cargando…

Current status of inherited pancreatic cancer

BACKGROUND: It is estimated that about 10% of pancreatic cancer cases have a genetic background. People with a familial predisposition to pancreatic cancer can be divided into 2 groups. The first is termed hereditary pancreatic cancer, which occurs in individuals with a known hereditary cancer syndr...

Descripción completa

Detalles Bibliográficos
Autores principales: Olakowski, Marek, Bułdak, Łukasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235234/
https://www.ncbi.nlm.nih.gov/pubmed/35761384
http://dx.doi.org/10.1186/s13053-022-00224-2
_version_ 1784736270097842176
author Olakowski, Marek
Bułdak, Łukasz
author_facet Olakowski, Marek
Bułdak, Łukasz
author_sort Olakowski, Marek
collection PubMed
description BACKGROUND: It is estimated that about 10% of pancreatic cancer cases have a genetic background. People with a familial predisposition to pancreatic cancer can be divided into 2 groups. The first is termed hereditary pancreatic cancer, which occurs in individuals with a known hereditary cancer syndrome caused by germline single gene mutations (e.g., BRCA1/2, CDKN2A). The second is considered as familial pancreatic cancer, which is associated with several genetic factors responsible for the more common development of pancreatic cancer in certain families, but the precise single gene mutation has not been found. AIM: This review summarizes the current state of knowledge regarding the risk of pancreatic cancer development in hereditary pancreatic cancer and familial pancreatic cancer patients. Furthermore, it gathers the latest recommendations from the three major organizations dealing with the prevention of pancreatic cancer in high-risk groups and explores recent guidelines of scientific societies on screening for pancreatic cancers in individuals at risk for hereditary or familial pancreatic cancer. CONCLUSIONS: In order to improve patients’ outcomes, authors of current guidelines recommend early and intensive screening in patients with pancreatic cancer resulting from genetic background. The screening should be performed in excellence centers. The scope, extent and cost-effectiveness of such interventions requires further studies.
format Online
Article
Text
id pubmed-9235234
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92352342022-06-28 Current status of inherited pancreatic cancer Olakowski, Marek Bułdak, Łukasz Hered Cancer Clin Pract Review BACKGROUND: It is estimated that about 10% of pancreatic cancer cases have a genetic background. People with a familial predisposition to pancreatic cancer can be divided into 2 groups. The first is termed hereditary pancreatic cancer, which occurs in individuals with a known hereditary cancer syndrome caused by germline single gene mutations (e.g., BRCA1/2, CDKN2A). The second is considered as familial pancreatic cancer, which is associated with several genetic factors responsible for the more common development of pancreatic cancer in certain families, but the precise single gene mutation has not been found. AIM: This review summarizes the current state of knowledge regarding the risk of pancreatic cancer development in hereditary pancreatic cancer and familial pancreatic cancer patients. Furthermore, it gathers the latest recommendations from the three major organizations dealing with the prevention of pancreatic cancer in high-risk groups and explores recent guidelines of scientific societies on screening for pancreatic cancers in individuals at risk for hereditary or familial pancreatic cancer. CONCLUSIONS: In order to improve patients’ outcomes, authors of current guidelines recommend early and intensive screening in patients with pancreatic cancer resulting from genetic background. The screening should be performed in excellence centers. The scope, extent and cost-effectiveness of such interventions requires further studies. BioMed Central 2022-06-27 /pmc/articles/PMC9235234/ /pubmed/35761384 http://dx.doi.org/10.1186/s13053-022-00224-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Olakowski, Marek
Bułdak, Łukasz
Current status of inherited pancreatic cancer
title Current status of inherited pancreatic cancer
title_full Current status of inherited pancreatic cancer
title_fullStr Current status of inherited pancreatic cancer
title_full_unstemmed Current status of inherited pancreatic cancer
title_short Current status of inherited pancreatic cancer
title_sort current status of inherited pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235234/
https://www.ncbi.nlm.nih.gov/pubmed/35761384
http://dx.doi.org/10.1186/s13053-022-00224-2
work_keys_str_mv AT olakowskimarek currentstatusofinheritedpancreaticcancer
AT bułdakłukasz currentstatusofinheritedpancreaticcancer